Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR

NCT03095456 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT03095456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03095456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR
Lead sponsor
Mylan Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 27, 2017
Completion date
November 25, 2017
Enrollment
207 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd, low peak inspiratory flow rate (pifr)